How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Organ Perfusion System Market
- By Organ Type: Kidney Perfusion System, Liver Perfusion System, Heart Perfusion System, Lung Perfusion System, Pancreas Perfusion System
- By Technology: Hypothermic Machine Perfusion (HMP), Normothermic Machine Perfusion (NMP), Subnormothermic Perfusion, Pulsatile Perfusion, Continuous Perfusion
- By Application: Organ Preservation, Organ Assessment and Viability Testing, Organ Reconditioning and Repair
- By End User: Hospitals and Transplant Centers, Organ Procurement Organizations (OPOs), Research and Academic Institutes, Biotechnology and Pharmaceutical Companies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Kidney Perfusion System leads By Organ Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 267 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.165 →
- 11 Company Profiles 12 players: SWOT & benchmarking p.173 →
Full report · locked preview
Everything inside the Organ Perfusion System Market report
A complete, evidence-based study - 11 chapters and 112 sections covering market size, segmentation across 4 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
Organ Type 5
Technology 5
Application 3
End User 4
Companies profiled
Organ Recovery Systems (a subsidiary of Medtronic)
TransMedics Group Inc.
XVIVO Perfusion AB
Bridge to Life Ltd.
Paragonix Technologies Inc.
Waters Medical Systems Inc.
OrganOx Ltd.
LifePort Inc.
Organ Assist B.V.
LifeCell Corporation (a subsidiary of Allergan)
Medtronic plc
Organ Recovery Systems
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Organ Recovery Systems (a subsidiary of Medtronic)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →TransMedics Group Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →XVIVO Perfusion AB
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bridge to Life Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Paragonix Technologies Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Waters Medical Systems Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →OrganOx Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →LifePort Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Organ Assist B.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →LifeCell Corporation (a subsidiary of Allergan)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Medtronic plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Organ Recovery Systems
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,932M by 2033 · 4.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Kidney Perfusion System45.7
- Liver Perfusion System16.4
- Heart Perfusion System8.4
- Lung Perfusion System12.0
- Pancreas Perfusion System17.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,383M → $1,979M · 4.6%
Europe$963.7M → $1,386M · 4.6%
Asia Pacific$879.9M → $1,257M · 4.6%
Latin America$544.7M → $709.8M · 3.4%
Middle East and Africa$419.0M → $564.6M · 3.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.402026
4.402027
4.422028
4.432029
4.442030
4.462031
4.462032
4.482033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Organ Recovery Systems (a subsidiary of Medtronic)21.1
- TransMedics Group Inc.11.2
- XVIVO Perfusion AB8.2
- Bridge to Life Ltd.11.0
- Paragonix Technologies Inc.13.0
- Waters Medical Systems Inc.7.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Organ Type17.2%
Technology25.6%
Application36.7%
End User20.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.6
- Europe23.5
- Asia Pacific21.3
- Latin America12.0
- Middle East and Africa9.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Organ Recovery Systems (a subsidiary of Medtronic) | 90 | 96 | 91 | 87 | 99 | 78 | 90 |
| TransMedics Group Inc. | 81 | 83 | 89 | 89 | 87 | 75 | 84 |
| XVIVO Perfusion AB | 86 | 69 | 75 | 75 | 81 | 82 | 78 |
| Bridge to Life Ltd. | 64 | 65 | 67 | 73 | 72 | 66 | 68 |
| Paragonix Technologies Inc. | 67 | 75 | 55 | 69 | 75 | 60 | 67 |
| Waters Medical Systems Inc. | 57 | 56 | 59 | 55 | 62 | 68 | 60 |
| OrganOx Ltd. | 58 | 64 | 46 | 52 | 50 | 55 | 54 |
| LifePort Inc. | 37 | 51 | 56 | 56 | 48 | 59 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Organ Recovery Systems (a subsidiary of Medtronic)
- TransMedics Group Inc.
- XVIVO Perfusion AB
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Organ Recovery Systems (a subsidiary of Medtronic) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| TransMedics Group Inc. | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| XVIVO Perfusion AB | ✓ | − | ✓ | ◐ | ◐ | ◐ |
| Bridge to Life Ltd. | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Paragonix Technologies Inc. | ◐ | ◐ | ◐ | ✓ | ◐ | − |
| Waters Medical Systems Inc. | ◐ | ◐ | ◐ | ◐ | − | ✓ |
| OrganOx Ltd. | − | − | ◐ | − | − | ◐ |
| LifePort Inc. | − | − | − | ◐ | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Organ Recovery Systems (a subsidiary of Medtronic)90
2TransMedics Group Inc.84
3XVIVO Perfusion AB78
4Bridge to Life Ltd.68
5Paragonix Technologies Inc.67
6Waters Medical Systems Inc.60
7OrganOx Ltd.54
8LifePort Inc.51
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Organ Recovery Systems (a subsidiary of Medtronic)TransMedics Group Inc.XVIVO Perfusion AB
Challenger2
Strong scale, closing on the leaders.
Bridge to Life Ltd.Paragonix Technologies Inc.
Contender1
Focused players with pockets of strength.
Waters Medical Systems Inc.
Niche2
Specialists in a single segment or region.
OrganOx Ltd.LifePort Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Organ Type in North America, then scale across Organ Perfusion System Market — a $837M beachhead inside a $13.0B market.
Beachhead (SOM)$837Mobtainable near-term
Serviceable (SAM)$4.68Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Kidney Perfusion System
Best fit — highest urgency & budget in Organ Type.
Economic buyer77 fit
Liver Perfusion System
Strong fit — clear ROI and a fast path to value.
End user68 fit
Heart Perfusion System
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Organ Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Technology & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel31%
Digital / self-serve17%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Organ Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Organ Perfusion System Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified21%
Evaluation12%
Closed-won6%
$14.5KCAC
$77KLTV
5.3:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Organ Perfusion System Market is a resilient opportunity — $5.14B by 2033, compounding at 4.4%.
TAM · 2025$3.64Btoday
TAM · 2033$5.14Bforecast
CAGR4.4%2027–2033
Cumulative$39.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.14BTotal addressable market
SAM$2.01BServiceable available market
SOM$410MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.4% CAGR
Demand compounds through 2033, outpacing GDP across Organ Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Organ Type moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.14BLarge & growingTAM by 2033 at 4.4% CAGR
$2.01BServiceable nowreachable with today’s model
$410MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.01BBear2.9% CAGR
$5.14BBase4.4% CAGR
$6.58BBull5.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Technology optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Organ Perfusion System Market — a $11.5B market by 2033. Plan: grow share from 9.0% to 16.1%.
Market size · 2033$11.5Btotal addressable
Market CAGR11.1%2027–2033
Target share16.1%from 9.0% today
Revenue ambition$1.85Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.0% | 16.1% | At risk |
| Revenue | $1.12B | $1.85B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 34.5% | 45.2% | Ahead |
| Customer retention | 87.0% | 92.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Organ Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Technology capability
A defensible second engine — invest in Technology to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Organ Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Technology
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $212M capacity & capability investment
- Greenlight bolt-on M&A in Technology
- Authorise North America expansion plan
- Fund R&D program for Organ Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Organ Perfusion System Market conversation — a $5.08B market you can size, segment and defend in minutes.
Market size · 2033$5.08Btotal opportunity
Growth11.1%CAGR to 2033
Addressable buyers1,527+accounts in scope
Typical ROI4.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Organ Type
Goal Grow share in Organ Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.6×return on cost, year one
< 4 mopayback period
$65K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
Organ Recovery Systems (a subsidiary of Medtronic)TransMedics Group Inc.XVIVO Perfusion ABBridge to Life Ltd.Paragonix Technologies Inc.Waters Medical Systems Inc.OrganOx Ltd.LifePort Inc.+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Organ Perfusion System Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Organ Perfusion System Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Organ Perfusion Solution Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportOrgan-on-a-chip Systems Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportOrganoids on Chips Model Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportOrganoids and 3D Cell Culture Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportOrganoid Natural Surface Market
Market size, share, segmentation and regional forecast.
$328M market · 2025 base year
View reportOrganoid Cytokines Market
Market size, share, segmentation and regional forecast.
$368M market · 2025 base year
View reportOrganoid Culture Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportOrganic Vitamin C supplement Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportOrganic Sublingual Liquid Vitamin Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportOrganic Skin Supplements Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportOrganic Scintillation Detector Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportOrganic Medicinal Mushroom Extract Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.